Recently diagnosed with HIV? Click here

TITAN (darunavir)

Clinical trial • Reported • 10 May 2007
This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.

About this trial

This study compares darunavir/r to lopinavir/r (the 'r' signifies that a small dose of ritonavir is also used) in people who are treatment experienced.

The study will compare these two approaches for their safety and tolerability, as well as their effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. in fighting HIV.

Background information

The effectiveness(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of protease inhibitors can often be improved by using a small dose of a second protease inhibitor (ritonavir) to 'boost' the level of drug in the bloodstream.  

Most protease inhibitors can be improved using this approach. In fact, lopinavir is never used alone and is only available in its boosted form under the brand name Kaletra.  

Official title:Trial of TMC114/Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Subjects
What is this trial studying?Existing drug – darunavir
How long is this trial planned to go for?Participants in this trial will be asked to take the trial drug for 32 weeks. Following the conclusion of the trial, participants will be followed up for a further 96 weeks.
Links to further information:
Can I access this treatment other than by enrolling in this trial?

Darunavir is now a registered PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. drug in Australia

Tags:rollover study, Special Assistance Schemes

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Viral load at least 1000 copies/ml
  • Have been taking combination antiviral treatment for at least 12 weeks

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Results:

See link above for summary of results from CROI 2007

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 10 May 2007 — more than five years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more